Member Info for Chazzy2

https://www.fiercebiotech.com/medtech/insilico-and-a2a-launch-new-duchenne-focused-ai-drug-company

Insilico collaboration with A2A bodes well for Juvenescence

https://twitter.com/LorneAbony/status/1019712218210938886

Loft's question is a fair one Pred. We know absolutely nothing about Yooya and so to speculate as to its valuation is pointless as this stage.

http://vemo.com/new-affordability-initiative-expands-access-opportunity-at-norwich-university/

What an amazing week! If the price can move like this without any RNS's, just wait until the newsflow.

Sorry - article not appearing when you open the link. Just google Juvenescence IPO and look at the FT article from June. Hopefully you'll read it that way!

https://www.ft.com/content/30bb0752-6d5e-11e8-92d3-6c13e5c92914

https://www.ft.com/content/30bb0752-6d5e-11e8-92d3-6c13e5c92914

Juvenescence plans for an IPO in 2019. Could be a huge uplift in valuation.

https://www.factom.com/blog/factom-ano-2nd-quarter-2018-review

https://www.factom.com/blog/factom-ano-2nd-quarter-2018-review.

Wonder who Factom inc.'s first official customer is then. The Factom team is continuing to expand. All good signs.

Yes great news about Leap. Shows a real vote of confidence in the company. I was really disappointed when they first announced that they were going to sell Leap having such a large stake in it, so am delighted that they are increasing their stake now. Leap have recently introduced football to their list of sports, so events like the World Cup and tennis at Wimbledon should hopefully spur a few more punters on. Revenues should really take off now with the tie-up with IMG.

Really encouraging update all round. I'm particularly glad that our two biggest holdings, Leap and Yooya have good updates. Yooya is in profit now and revenues growing month on month. Would love to see some revenue figures but I suppose all in good time. Leap must be growing substantially now with all the tie ins with gamers and relaxation of the gambling regulations in the US. And our latest two investments look realky good too. Vogogo is an income generator and juvenescence has huge potential upside with the thousands of drugs it can license at $30-40 million per drug.
Ffwd book value NAV is fast catching up with its market cap which should strongly underpin the sp now. Really exciting future for FFWD.

You'd better watch out, you'd better beware, Lorne says E=mc2, Einstein vogogo!

Up 14% today!

The battering in the sp of FFWD was a reminder of how erratic the aim market can be at times, and must have seemed like a real kick in the teeth to all shareholders, including myself. But savvy investors will realise that the sp drop in no way reflects the excellent progress that has been made in recent months.
Look at the facts a moment.
The market cap is currently about £16m. We are sitting on about £6m in cash. Leap which was valued at about 4m a year ago has tied up with IMG and that combined with a relaxation in the US gambling laws must now value Leap at at least 8m now. That leaves Factom, Yooya, Vemo, Intensity, Juvenescence and Vogogo with a combined value of 2m. I don't think so some how!
Take a look at this presentation by Insilico (part of the Juvenescence portfolio) Insilico has about 2000 drugs it is ready to license to big pharma for $30 - 40 million per drug. Even if it licences just 1% of those drugs the revenues generated should make Insilico a multibillion dollar company. Insilico is at the forefront of drug discovery using AI. So the upside for Juvenescence alone I think will be enormous.

https://www.youtube.com/watch?v=_sHS0laAgu8

Lorne himself has just tweeted about the huge progress that factom, Leap and Yooya are making in addition.
So I think the facts speak for themselves. We have a terrific portfolio and soon the market will wake up to this fact. GLA

They are seeking FDA approval in both applications. The ovarian study was a success in clinical trials, however a follow up trial will be needed which incorporates the measurement of other biomarkers in order to increase further the sensitivity percentages in correctly predicting the presence of ovarian cancer. The Metastatic breast cancer clinical trial has been simultaneously taking place in the US and is due to read out in the autumn. Assuming the results are a success FDA approval should then follow a few months later. So FDA approval is being sought for metastatic breast cancer first, and the ovarian cancer later once the further trial has been completed.

Investment in Juvenescence is a smart move, with its underlying companies right at the forefront of longevity research. Drug discovery has reached a new era of making the needle, rather than finding the needle in the haystack, and Insilico medicine is one of the leading companies behind this innovation. Watch this video for an idea as to the revenue potential for Insilico. https://www.youtube.com/watch?v=_sHS0laAgu8 Jim Mellon and the team know what they're doing, and shareholders just need the patience to let them do it. Great price to get in at FFWD.

Paul Snow's own words. "Let's be clear. Factom is not in control on the release of information about our clients; Our Clients are in control. We are not going to cross some line where all the sudden all our clients change their spots and start talking about their plans and development with Factom. They are going to talk about their plans and their projects when it is in their best interest, according to their judgement."

FFWD pulled off a masterstroke with its 5x return on its Nuuvera investment in less than one year. As a result FFWD is in a strong cash position. I'm sure the board are looking at various options as to how to reinvest some of that cash. Yes it was disappointing that Aphria had to be sold, but the board had no choice due to uk laws. Anyone still interested in Aphria can still invest directly so it should not be too much of an issue. The news about Leap Gaming couldn't have been better timed either with the gambling laws being relaxed in the US and the world cup and other major sporting events around the corner. Leap is afterall our largest holding and in a hugely growing industry so it always made sense to hold it for the medium term. The problem as I see it and the reason why the price has dropped in recent days is that with a conventional fund or investment trust the NPV of all the underlying investments is generally roughly that of the fund's market cap.. However the NPV of all of FFWD's investments based on book value has always lagged behind FFWD's market cap by a wide margin, and it's only now that we are seeing the gap begin to close. The sp is now valuing factom, Yooya, Intensity, Leap gaming etc. still at book value when we know significant progress is being made with most of the companies held. It will only take one good IPO of factom, Yooya, Leap etc for our NPV to shoot ahead of the current market cap. Only then I feel will we really see sparks fly with the sp of FFWD. But credit to the board. They may not do interviews on Proactive Investor or on BRR media like some companies do, but in their own quiet way they are delivering the goods, despite what many think.

https://www.bbc.co.uk/news/world-us-canada-44407795 Brief mention of Aphria in BBC's reporting of the Canadian vote to legalise recreational cannabis. Don't hold your breath for an RNS folks. The board probably reckon that Google and Twitter can do the job for them, and they're probably right, and do a better job!